FrancophonIA/ELRC3.0 huggingface dataset:
English: The most common side effects with Cometriq (which may affect more than 2 in 10 people) are diarrhoea, palmar-plantar erythrodysaesthesia syndrome (hand-foot syndrome, which involves rash and numbness on the palms and soles), loss of weight, loss of appetite, nausea (feeling sick), tiredness, taste disturbances, changes in hair colour, hypertension (high blood pressure), inflammation of the mucosa (moist tissue that lines certain body cavities) including stomatitis (inflammation of the lining of the mouth), constipation, vomiting, weakness, and changes in the sound of the voice.
Croatian: Najčešće nuspojave lijeka Cometriq (kod više od 2 na 10 osoba) su proljev, sindrom palmarnoplantarne eritrodizestezije (sindrom šaka-stopalo koji uključuje osip i tupost u dlanovima i tabanima), gubitak tjelesne težine, gubitak apetita, mučnina (osjećaj slabosti), umor, poremećaji okusa, promjene boje kose, hipertenzija (visoki krvni tlak), upala sluznice (vlažnog tkiva koje obavija tjelesne šupljine) uključujući stomatitis (upalu sluznice usta), zatvor, povraćanje, slabost i promjene boje glasa.
English: The most common abnormal results in laboratory blood tests were increased liver enzymes such as aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP), low white cell counts (lymphopenia or neutropenia), thrombocytopenia (low blood-platelet counts), hypocalcaemia (low blood calcium levels), hypophosphataemia (low blood levels of phosphates), hypomagnesaemia (low blood magnesium levels), hypokalaemia (low blood potassium levels) and hyperbilirubinaemia (increased amounts of bilirubin, a breakdown product of red blood cells).
Croatian: Najčešći abnormalni rezultati laboratorijskih krvnih pretraga bili su povišeni enzimi jetre, poput aspartat aminotransferaze (AST), alanin aminotransferaze (ALT) i alkalin fosfataze (ALP), mali broj bijelih krvnih stanica (limfopenija ili neutropenija), trombocitopenija (mali broj trombocita), hipokalcemija (niske razine kalcija u krvi), hipofosfatemija (niske razine fosfata u krvi), hipomagnezijemija (niske razine magnezija u krvi), hipokalemija (niske razine kalija u krvi) i hiperbilirubinemija (povišene količine bilirubina, proizvoda razgradnje crvenih krvnih stanica).
English: Cometriq can only be obtained with a prescription and treatment should only be started by a doctor who has experience in using cancer medicines.
Croatian: Cometriq se izdaje samo na liječnički recept, a terapiju lijekom mora započeti liječnik koji ima iskustva s primjenom citotoksičnih lijekova.
English: What information is still awaited for Cometriq?
Croatian: Koje se još informacije očekuju o lijeku Cometriq?
English: Cometriq had shown a benefit in patients with advanced medullary thyroid cancer unsuitable for surgery, who have few other treatment options.
Croatian: Korist od lijeka Cometriq dokazana je u bolesnika s inoperabilnim uznapredovalim medularnim karcinomom štitnjače, koji imaju malo drugih mogućnosti liječenja.
English: The most common serious side effects are pneumonia, inflammation of the mucosa, hypocalcaemia (low calcium levels in the blood), dysphagia (difficulty swallowing), dehydration, pulmonary embolism (blood clots in the vessels supplying the lungs), and hypertension.
Croatian: Najčešće ozbiljne nuspojave uključuju pneumoniju, upalu sluznice, hipokalcemiju (niske razine kalcija u krvi), disfagiju (poteškoće pri gutanju), dehidraciju, pulmonarnu emboliju (krvne ugruške u krvnim žilama koje opskrbljuju pluća) i hipertenziju.
English: For the full list of all side effects and restrictions with Cometriq, see the package leaflet.
Croatian: Potpuni popis nuspojava i ograničenja pri primjeni lijeka Cometriq potražite u uputi o lijeku.
English: How does Cometriq work?
Croatian: Kako djeluje Cometriq?
English: How is Cometriq used?
Croatian: Kako se Cometriq koristi?
English: For practical information about using Cometriq, patients should read the package leaflet or contact their doctor or pharmacist.
Croatian: Praktične informacije o primjeni lijeka Cometriq pročitajte u uputi o lijeku, odnosno obratite se svojem liječniku ili ljekarniku.
English: What benefits of Cometriq have been shown in studies?
Croatian: Koje su koristi lijeka Cometriq utvrđene u ispitivanjima?
English: Date of first authorisation: 29 May 2006.
Croatian: Datum prvog odobrenja: 29. svibnja 2006.
English: 2 to 6 weeks depending on toxicity and response.
Croatian: 2 do 6 tjedana, ovisno o toksičnosti i odgovoru.
English: Your doctor will give you Evoltra once every day for 5 days.
Croatian: Liječnik će Vam lijek Evoltra davati jednom na dan tijekom 5 dana.
English: What Evoltra is and what it is used for
Croatian: Što je Evoltra i za što se koristi
English: Evoltra may harm both male and female reproductive organs.
Croatian: Evoltra može naškoditi i muškim i ženskim reproduktivnim organima.
English: Other medicines and Evoltra
Croatian: Drugi lijekovi i Evoltra
English: EU/1/06/334/001 3 vials EU/1/06/334/002 4 vials EU/1/06/334/003 10 vials EU/1/06/334/004 20 vials EU/1/06/334/005 1 vial
Croatian: EU/1/06/334/001 3 bočice EU/1/06/334/002 4 bočice EU/1/06/334/003 10 bočica EU/1/06/334/004 20 bočica EU/1/06/334/005 1 bočica
English: Estimates based on non-compartmental analysis (n = 14 / n = 14)
Croatian: Procjene temeljene na nekompartmentalnoj analizi (n = 14 / n = 14)
English: PR = Partial Remission
Croatian: PR = parcijalna remisija
English: Most of the cardiac adverse events were reported in the first 2 cycles.
Croatian: Većina srčanih štetnih događaja prijavljena je tijekom prva 2 ciklusa.
English: Evoltra is for single use only.
Croatian: Evoltra je namijenjena samo za jednokratnu uporabu.
English: Adults (> 21 and < 65 years old)
Croatian: Odrasli (u dobi > 21 i < 65 godina)
English: After 24 hours, about 60% of the dose is excreted unchanged in the urine.
Croatian: Nakon 24 sata otprilike 60% doze izluči se mokraćom u nepromijenjenom obliku.
English: Therefore, Evoltra should not be used during pregnancy, especially not during the first trimester, unless clearly necessary (i.e. only if the potential benefit to the mother outweighs the risk to the foetus).
Croatian: Stoga se lijek Evoltra ne smije primjenjivati tijekom trudnoće, naročito tijekom prvog tromjesečja, osim ako to nije neophodno (tj. ako potencijalna korist za majku nadilazi rizik za plod).
English: Volume of distribution (steady state)
Croatian: Volumen distribucije (stanje dinamičke ravnoteže)
English: Each box contains 1, 3, 4, 10 or 20 vials.
Croatian: Jedna kutija sadrži 1, 3, 4, 10 ili 20 bočica.
English: From a microbiological point of view, it should be used immediately.
Croatian: S mikrobiološkog stajališta, lijek se mora odmah primijeniti.
English: Pharmacotherapeutic group: Antineoplastic agents, antimetabolites, ATC code: L01BB06.
Croatian: Farmakoterapijska skupina: Antineoplastici, antimetaboliti, ATK oznaka: L01BB06.
English: Evoltra contains salt
Croatian: Evoltra sadrži sol
English: Each box contains 1, 3, 4, 10 or 20 vials, but not all pack sizes may be marketed.
Croatian: Jedna kutija sadrži 1, 3, 4, 10 ili 20 bočica, ali na tržištu se ne moraju nalaziti sve veličine pakiranja.
English: This medicine has been authorised under “Exceptional Circumstances”.
Croatian: Ovaj lijek je odobren u ‘iznimnim okolnostima'.
English: What you need to know before you use Evoltra
Croatian: Što morate znati prije nego počnete primjenjivati lijek Evoltra
English: Tell your doctor if you are on a controlled sodium diet as it could affect how you will be given your medicine.
Croatian: Recite liječniku ako ste na režimu prehrane s ograničenim unosom soli jer to može utjecati na način na koji će lijek biti primijenjen.
English: (If the use of a 0.2 micrometre syringe filter is not feasible, the concentrate should be pre-filtered with a 5 micrometre filter, diluted and then administered through a 0.22 micrometre in-line filter.)
Croatian: (Ako primjena štrcaljke s filtrom od 0,2 mikrometra nije moguća, koncentrat treba prethodno filtrirati kroz filtar od 5 mikrometara, razrijediti i potom primijeniti kroz linijski filtar od 0,22 mikrometra.)
English: Body surface area (m
Croatian: Površina tijela (m2)
English: CR = Complete Remission
Croatian: KR = kompletna remisija
English: • Patients who met all of the criteria for a CR except for recovery of platelet counts to > 100 x 10
Croatian: • bolesnici koji zadovoljavaju sve kriterije za KR, osim oporavka broja trombocita do > 100 x 109/l
English: Where follow-up data are available, the majority of bilirubin elevations returned to  grade 2 within 10 days.
Croatian: U slučajevima gdje postoje podaci o praćenju, povišena vrijednost bilirubina većinom se vratila na stupanj ≤ 2 u roku od 10 dana.
English: Clear, practically colourless solution with a pH of 4.5 to 7.5 and an osmolarity of 270 to 310 mOsm/l.
Croatian: Bistra, gotovo bezbojna otopina pH vrijednosti od 4,5 do 7,5 i osmolarnosti od 270 do 310 mOsm/l.
English: Evoltra must not be mixed with or concomitantly administered using the same intravenous line as other medicinal products (see section 6.2).
Croatian: Evoltra se ne smije miješati niti primjenjivati istodobno s drugim lijekovima kroz istu intravensku liniju (vidjeti dio 6.2).
English: • An M2 bone marrow ( 5% and ≤ 25% blasts) and appearance of normal progenitor cells
Croatian: • koštana srž M2 (≥ 5% i ≤ 25% blasta) i pojava normalnih progenitornih stanica
English: CR * Duration of remission censored at the time of transplant ** Patient received a transplant following alternate therapy *** Patient received a transplant following relapse
Croatian: KR * Trajanje remisije cenzurirano u trenutku transplantacije ** Bolesnik je transplantiran nakon zamjenskog liječenja *** Bolesnik je transplantiran nakon relapsa
English: Treatment cycles should be repeated every 2 to 6 weeks (from the starting day of the previous cycle) following recovery of normal haematopoiesis (i.e. ANC ≥ 0.75 × 10
Croatian: Cikluse liječenja treba ponavljati svakih 2 do 6 tjedana (od prvog dana prethodnog ciklusa) nakon ponovne uspostave normalne hematopoeze (tj. ABN ≥ 0,75 × 109/l)
English: If you forget to use Evoltra
Croatian: Ako ste zaboravili primijeniti lijek Evoltra
English: It will be given to you as an infusion through a long thin tube which goes into a vein (a drip), or into a small medical appliance that is inserted under the skin (port-a-cath) if you (or your child) have one implanted.
Croatian: Lijek će se primijeniti u obliku infuzije kroz dugačku tanku cjevčicu koja ulazi u venu (drip) ili u mali medicinski uređaj koji se umeće ispod kože (kateter "port-a-cath") ako Vi (ili Vaše dijete) imate takav uređaj.
English: However, because of the potential for serious adverse reactions in nursing infants, breastfeeding should be discontinued prior to, during and following treatment with Evoltra (see section 4.3).
Croatian: Međutim, zbog mogućnosti javljanja ozbiljnih nuspojava u dojenčadi, dojenje se mora prekinuti prije, tijekom i nakon liječenja lijekom Evoltra (vidjeti dio 4.3).
English: • The use of prophylactic steroids (e.g., 100 mg/m hydrocortisone on Days 1 through 3) may be of benefit in preventing signs or symptoms of SIRS or capillary leak.
Croatian: • Profilaktička primjena steroida (npr. 100 mg/m2 hidrokortizona od 1. do 3. dana) može biti korisna za sprječavanje znakova ili simptoma SIRS-a ili povećane propusnosti kapilara.
English: • If you have any further questions, ask your doctor.
Croatian: • Ako imate dodatnih pitanja, obratite se svome liječniku.
English: No studies on the effects of clofarabine on the ability to drive and use machines have been performed.
Croatian: Nisu provedena ispitivanja utjecaja klofarabina na sposobnost upravljanja vozilima i rada sa strojevima.
English: Evoltra may not be suitable for you: - if you have suffered a severe reaction after previously using this medicine; - if you have kidney disease, or used to have it; - if you have liver disease, or used to have it;
Croatian: Evoltra možda neće biti prikladna za Vas: - ako ste doživjeli tešku reakciju nakon prethodnog uzimanja ovog lijeka; - ako imate ili ste imali bolest bubrega; - ako imate ili ste imali bolest jetre; - ako imate ili ste imali bolest srca.
English: 1105 BP AmsterdamThe Netherlands
Croatian: 1105 BP Amsterdam Nizozemska
English: • Prophylactic administration of allopurinol should be considered if hyperuricemia (tumour lysis) is expected.
Croatian: • Treba razmotriti profilaktičku primjenu alopurinola ako se očekuje pojava hiperuricemije (lize tumora).
English: During treatment with Evoltra, your doctor will carry out regular blood tests and other tests to monitor your health.
Croatian: Tijekom liječenja lijekom Evoltra liječnik će redovito provoditi krvne i druge pretrage radi praćenja Vašeg zdravstvenog stanja.
English: • DNA polymerase  inhibition resulting in termination of DNA chain elongation and/or DNA synthesis / repair.
Croatian: • inhibiciji DNK polimeraze α, kojom se zaustavlja elongacija lanca DNK i/ili sinteza/popravak DNK
English: • Complete disappearance of circulating blasts
Croatian: • potpuni nestanak blasta iz krvotoka
English: Your treatment with Evoltra has been prescribed by a qualified doctor experienced in treating leukaemia.
Croatian: Liječenje lijekom Evoltra propisuje kvalificirani liječnik s iskustvom u liječenju leukemije.
English: Concentrate for solution for infusion 20 mg/20 ml
Croatian: Koncentrat za otopinu za infuziju 20 mg/20 ml
English: The threshold for developmental toxicity was considered to be 6 mg/m 2/day in rats and 1.2 mg/m 2/day in rabbits.
Croatian: Smatra se da je prag za razvojnu toksičnost bio 6 mg/m2 na dan u štakora i 1,2 mg/m2 na dan u kunića.
English: Pericardial effusion and pericarditis were reported as an adverse event in 9% (10/115) of patients.
Croatian: Perikardni izljev i perikarditis prijavljeni su kao štetni događaj u 9% (10/115) bolesnika.
English: Plasma protein binding Serum albumin Elimination:  half-life of clofarabine
Croatian: Vezanje za proteine u plazmi Albumin u serumu Eliminacija: β poluvijek klofarabina
English: The most frequent haematological laboratory abnormalities observed in patients treated with clofarabine were anaemia (83.3%; 95/114); leucopaenia (87.7%; 100/114); lymphopaenia (82.3%; 93/113), neutropaenia (63.7%; 72/113), and thrombocytopaenia (80.7%; 92/114).The majority of these events were of grade  3.
Croatian: Najčešći hematološki poremećaji u laboratorijskim nalazima primijećeni u bolesnika liječenih klofarabinom bili su anemija (83,3%; 95/114); leukopenija (87,7%; 100/114); limfopenija (82,3%; 93/113), neutropenija (63,7%; 72/113) i trombocitopenija (80,7%; 92/114).
English: 1 vial 3 vials 4 vials 10 vials 20 vials
Croatian: 1 bočica 3 bočice 4 bočice 10 bočica 20 bočica
English: Once prepared and diluted, Evoltra should be used straight away or within 24 hours if stored in a refrigerator (at 2
Croatian: Nakon pripreme za primjenu i razrjeđivanja lijek Evoltra treba primijeniti odmah ili unutar 24 sata ako se čuva u hladnjaku (na temperaturi od 2°C do 8°C).
English: Before Evoltra is given to you, it will be diluted in a sodium chloride solution (salt and water).
Croatian: Evoltra će se prije primjene razrijediti u otopini natrijevog klorida (sol i voda).
English: It should be filtered through a sterile 0.2 micrometre syringe filter and then diluted with sodium chloride 9 mg/ml (0.9%) intravenous infusion to produce a total volume according to the examples given in the table below.
Croatian: Treba ga filtrirati kroz štrcaljku sa sterilnim 0,2-mikrometarskim filtrom i potom razrijediti s otopinom natrijevog klorida za intravensku infuziju od 9 mg/ml (0,9%) kako bi se dobio ukupan volumen koji odgovara primjerima navedenima u tablici u nastavku.
English: It is a clear, almost colourless solution that is prepared and diluted before it is used.
Croatian: Lijek je bistra i gotovo bezbojna otopina koja se prije uporabe mora pripremiti za primjenu i razrijediti.
English: These infections may lead to septic shock, respiratory failure, renal failure, and/or multiorgan failure.
Croatian: Te infekcije mogu dovesti do septičkog šoka, zatajenja disanja, zatajenja bubrega i/ili višestrukog zatajenja organa.
English: See the section ‘Pregnancy and breast-feeding' below.
Croatian: Pogledajte dio "Trudnoća i dojenje" u nastavku teksta.
English: The majority of elevations in ALT and AST occurred within 10 days of clofarabine administration and returned to  grade 2 within 15 days.
Croatian: Do povišenja vrijednosti ALT-a i AST-a većinom je došlo unutar 10 dana od primjene klofarabina, a vratile su se na stupanj ≤ 2 u roku od 15 dana.
English: If you are the parent of a child who is being treated with Evoltra, tell the doctor if any of the above conditions apply to your child.
Croatian: Ako ste roditelj djeteta koje se liječi lijekom Evoltra, obavijestite liječnika ako se bilo što od gore navedenog odnosi na Vaše dijete.
English: Adverse reactions are listed by system organ class and frequency (very common ( 1/10); common ( 1/100 to < 1/10), uncommon ( 1/1,000 to < 1/100; rare ( 1/10,000 to < 1/1,000) and very rare (< 1/10,000)) in the table below.
Croatian: < 1/10), manje često (≥ 1/1000 i < 1/100), rijetko (≥ 1/10 000 i < 1/1000) i vrlo rijetko (< 1/10 000)) u tablici koja slijedi.
English: If a patient becomes pregnant during treatment with clofarabine, they should be informed of the possible hazard to the foetus.
Croatian: Ako bolesnica zatrudni tijekom liječenja klofarabinom, treba je upozoriti na moguću opasnost za plod.
English: CRp = Complete Remission in the Absence of Total Platelet Recovery
Croatian: KRt = kompletna remisija bez potpunog oporavka trombocita
English: Patients who did not undergo transplant CR
Croatian: Bolesnici koji nisu transplantirani
English: In addition, clofarabine possesses greater resistance to cellular degradation by adenosine deaminase and decreased susceptibility to phosphorolytic cleavage than other active substances in its class whilst the affinity of clofarabine triphosphate for DNA polymerase  and ribonucleotide reductase is similar to or greater than that of deoxyadenosine triphosphate.
Croatian: Osim toga, klofarabin ima veću otpornost na staničnu razgranju djelovanjem adenozin deaminaze i manju osjetljivost na fosforilitičko cijepanje od drugih djelatnih tvari u svojoj skupini, dok je afinitet klofarabin trifosfata prema DNK polimerazi α i ribonukleotid reduktazi podjednak ili viši od afiniteta deoksiadenozin trifosfata.
English: The information provided is based on data generated from clinical trials in which 115 patients (> 1 and ≤ 21 years old) with either ALL or acute myeloid leukaemia (AML) received at least one dose of clofarabine at the recommended dose of 52 mg/m daily x 5.
Croatian: Navedene informacije temelje se na podacima iz kliničkih ispitivanja u kojima je 115 bolesnika (u dobi > 1 i ≤ 21 godine) s akutnom limfoblastičnom leukemijom (ALL) ili akutnom mijeloičnom leukemijom (AML) primilo barem jednu dozu klofarabina u preporučenoj dozi od 52 mg/m2 na dan x 5.
English: • An M1 marrow that did not qualify for CR or CRp
Croatian: • koštana srž M1 koji ne zadovoljava kriterije za KR ili KRt
English: To date, the highest daily dose administered to human beings is 70 mg/m for 5 consecutive days (2 paediatric ALL patients).
Croatian: Najviša dosad primijenjena doza u ljudi je 70 mg/m2 na dan tijekom 5 uzastopnih dana (2 pedijatrijska bolesnika s ALL-om).
English: You need to allow for this if you are on a controlled sodium diet.
Croatian: To morate uzeti u obzir ako ste na režimu prehrane s ograničenim unosom soli.
English: Evoltra should not be handled by pregnant women.
Croatian: Trudnice ne smiju rukovati lijekom Evoltra.
English: The liver is a potential target organ for clofarabine toxicity and 25.2% of patients experienced at least one hepato-biliary disorders adverse event (see sections 4.3 and 4.4).
Croatian: Jetra je potencijalni ciljni organ toksičnog učinka klofarabina pa se u 25,2% bolesnika javio barem jedan štetni događaj u obliku poremećaja jetre i žuči (vidjeti dijelove 4.3 i 4.4).
English: If you are the parent of a child who is being treated with Evoltra, tell the doctor if any of them apply to your child.
Croatian: Ako ste roditelj djeteta koje se liječi lijekom Evoltra, obavijestite liječnika ako se bilo što od navedenog odnosi na Vaše dijete.
English: • Periodic Safety Updated Reports
Croatian: • Periodička izvješća o neškodljivosti
English: Tell your doctor if you are using or have recently used: - medicines for heart disease; - any medicine that changes your blood pressure; - medicines that affect your liver or kidneys; - any other medicines including those obtained without a prescription.
Croatian: - lijekove za liječenje bolesti srca; - bilo koji lijek koji utječe na krvni tlak; - lijekove koji utječu na jetru ili bubrege; - bilo koje druge lijekove, uključujući one koje ste nabavili bez recepta.
English: Systemic inflammatory response syndrome (SIRS) or capillary leak syndrome SIRS, capillary leak syndrome (signs and symptoms of cytokine release, e.g., tachypnea, tachycardia, hypotension, pulmonary oedema) were reported as an adverse event in 5% (6/115) of paediatric patients (5 ALL, 1 AML) (see section 4.4).
Croatian: Sindrom sistemskog upalnog odgovora (SIRS) ili sindrom povećane propusnosti kapilara Sindrom sistemskog upalnog odgovora, sindrom povećane propusnosti kapilara (znakovi i simptomi otpuštanja citokina, npr. tahnipneja, tahikardija, hipotenzija, plućni edem) prijavljeni su kao štetni događaj u 5% (6/115) pedijatrijskih bolesnika (5 ALL, 1 AML) (vidjeti dio 4.4).
English: Do not use this medicine after the expiry date which is stated on the vial label and box after EXP.
Croatian: Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na naljepnici bočice i na kutiji iza „Rok valjanosti“.
English: (59%), febrile neutropaenia (35%), headache (24%), rash (21%), diarrhoea (20%), pruritus (20%), pyrexia (19%), palmar-plantar erythrodysaesthesia syndrome (15%), fatigue (14%), anxiety (12%), mucosal inflammation (11%), and flushing (11%).
Croatian: Najčešće prijavljeni bili su mučnina (61% bolesnika), povraćanje (59%), neutropenijska vrućica (35%), glavobolja (24%), osip (21%), proljev (20%), pruritus (20%), pireksija (19%), sindrom palmarno-plantarne eritrodizestezije (15%), umor (14%), anksioznost (12%), upala sluznice (11%) i navale crvenila (11%).
English: It was observed that the frequency and severity of adverse reactions, in particular infection, myelosuppression (neutropenia) and hepatotoxicity, are increased when clofarabine is used in combination.
Croatian: Primjećena je povećana učestalost i težina nuspojava, posebno infekcije, mijelosupresije (neutropenija) i hepatotoksičnosti, kada se klofarabin koristi u kombinaciji.
English: Intravenous infusion of 52 mg/m clofarabine produced equivalent exposure across a wide range of weights.
Croatian: Intravenska infuzija doze klofarabina od 52 mg/m2 rezultirala je jednakom izloženošću kod različitih tjelesnih težina.
English: However, the pharmacokinetics of clofarabine in adults with relapsed or refractory AML following administration of a single dose of 40 mg/m clofarabine by intravenous infusion over 1 hour were comparable to those described above in patients aged between 2 to 19 years old with relapsed or refractory ALL or AML following administration of 52 mg/m clofarabine by intravenous infusion over 2 hours for 5 consecutive days.
Croatian: Međutim, farmakokinetika klofarabina u odraslih s relapsnom ili refraktornom AML nakon primjene jednokratne doze klofarabina od 40 mg/m2 intravenskom infuzijom tijekom 1 sata bila je usporediva s prethodno opisanom farmakokinetikom u bolesnika u dobi od 2 do 19 godina s relapsnom ili refraktornom ALL ili AML nakon primjene doze klofarabina od 52 mg/m2 intravenskom infuzijom tijekom 2 sata kroz 5 uzastopnih dana.
English: Clofarabine is eliminated by a combination of renal and non-renal excretion.
Croatian: Klofarabin se eliminira kombinacijom bubrežnog i nebubrežnog izlučivanja.